Business Combinations (Narrative) (Details) $ / shares in Units, $ in Thousands |
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
|
|
|
Oct. 03, 2021
USD ($)
employees
|
Apr. 04, 2021
USD ($)
|
Oct. 04, 2020
USD ($)
|
Oct. 03, 2021
USD ($)
employees
$ / shares
shares
|
Oct. 04, 2020
USD ($)
|
Jan. 03, 2021
USD ($)
employees
$ / shares
|
Sep. 17, 2021
$ / shares
|
Jul. 04, 2021
USD ($)
|
Jul. 05, 2020
USD ($)
|
Dec. 29, 2019
USD ($)
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions |
|
|
|
1 year
|
|
|
|
|
|
|
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
$ 37,225
|
|
$ 2,817
|
$ 37,225
|
$ 2,817
|
$ 2,953
|
|
$ 3,334
|
$ 13,726
|
$ 35,481
|
Total transaction costs |
(72,500)
|
|
(200)
|
(87,600)
|
(7,400)
|
|
|
|
|
|
Goodwill |
7,420,271
|
|
|
7,420,271
|
|
3,447,114
|
|
|
|
|
Business Combination, Contingent Consideration, Liability, Current |
4,200
|
|
|
4,200
|
|
2,900
|
|
|
|
|
Business Combination, Contingent Consideration, Liability, Noncurrent |
33,000
|
|
|
33,000
|
|
100
|
|
|
|
|
Foreign Currency Transaction Gain (Loss), before Tax |
1,100
|
|
1,900
|
500
|
(1,600)
|
|
|
|
|
|
Interest Expense |
43,531
|
|
12,057
|
74,407
|
37,308
|
|
|
|
|
|
Business Combination, Contingent Consideration, Liability |
37,200
|
|
|
37,200
|
|
3,000
|
|
|
|
|
Business Combination, Acquisition Related Costs |
$ 72,500
|
|
200
|
$ 87,600
|
7,400
|
|
|
|
|
|
Oxford Immunotec [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Entity Number of Employees | employees |
275
|
|
|
275
|
|
|
|
|
|
|
Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Combination, Consideration Transferred |
|
|
|
$ 958,915
|
|
|
|
|
|
|
Cash Acquired |
|
|
|
195,010
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets |
$ 73,933
|
|
|
73,933
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment |
26,507
|
|
|
26,507
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets |
15,564
|
|
|
15,564
|
|
|
|
|
|
|
Cash paid to the shareholders |
|
|
|
1,118,884
|
|
|
|
|
|
|
Business Combination, Consideration Transferred, Liabilities Incurred |
|
|
|
$ 910
|
|
|
|
|
|
|
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life |
|
|
|
12 years 4 months 24 days
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value |
|
|
|
$ 34,131
|
|
|
|
|
|
|
Goodwill |
527,402
|
|
|
527,402
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt |
58,594
|
|
|
58,594
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
$ 958,915
|
|
|
958,915
|
|
|
|
|
|
|
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable |
|
|
|
$ 0
|
|
|
|
|
|
|
Nexcelom Bioscience [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Entity Number of Employees | employees |
130
|
|
|
130
|
|
|
|
|
|
|
BioLegend [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition, Pro Forma Revenue |
|
|
|
$ 3,943
|
|
4,025
|
|
|
|
|
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual |
|
|
|
12,100
|
|
|
|
|
|
|
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual |
|
|
|
6,200
|
|
|
|
|
|
|
Business Combination, Consideration Transferred |
|
|
|
5,688,602
|
|
|
|
|
|
|
Cash Acquired |
|
|
|
292,377
|
|
|
|
|
|
|
Cash Acquired from Acquisition |
|
|
|
(292,400)
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Cash |
|
|
|
3,300,000
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Consideration Paid in Common Stock |
|
|
|
2,600,000
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets |
$ 184,541
|
|
|
184,541
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment |
147,200
|
|
|
147,200
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets |
$ 9,330
|
|
|
$ 9,330
|
|
|
|
|
|
|
Entity Number of Employees | employees |
700
|
|
|
700
|
|
|
|
|
|
|
Cash paid to the shareholders |
|
|
|
$ 3,335,753
|
|
|
|
|
|
|
Business Combination, Consideration Transferred, Liabilities Incurred |
|
|
|
$ 6,857
|
|
|
|
|
|
|
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life |
|
|
|
16 years 3 months 18 days
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value |
|
|
|
$ 0
|
|
|
|
|
|
|
Goodwill |
$ 3,511,498
|
|
|
3,511,498
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt |
38,240
|
|
|
38,240
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
5,688,602
|
|
|
5,688,602
|
|
|
|
|
|
|
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax |
|
|
|
$ 797
|
|
$ 552
|
|
|
|
|
Business Acquisition, Pro Forma Earnings Per Share, Basic | $ / shares |
|
|
|
$ 6,280
|
|
$ 4,390
|
|
|
|
|
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ / shares |
|
|
|
$ 6,260
|
|
$ 4,370
|
|
|
|
|
Foreign Currency Transaction Gain (Loss), before Tax |
|
|
|
$ (5,400)
|
|
|
|
|
|
|
Interest Expense |
|
|
|
$ 23,600
|
|
|
|
|
|
|
Business Acquisition, Share Price | $ / shares |
|
|
|
|
|
|
$ 187.56
|
|
|
|
Stock Issued During Period, Shares, Acquisitions | shares |
|
|
|
14,066,799
|
|
|
|
|
|
|
Business Combination, Acquisition Related Costs, Excluded From Proforma Income (Loss) From Continuing Operations |
|
|
|
$ 43,200
|
|
|
|
|
|
|
Business Combination, Bridge Financing and Debt Pre-issuance Hedging Costs, Excluded From Proforma Income (Loss) From Continuing Operations |
|
|
|
23,300
|
|
|
|
|
|
|
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable |
|
|
|
2,638,369
|
|
|
|
|
|
|
Fiscal Year 2020 Acquisitions [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments |
|
$ 384
|
|
|
|
|
|
|
|
|
Business Combination, Consideration Transferred |
|
412,097
|
|
|
|
|
|
|
|
|
Cash Acquired |
|
(26,840)
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets |
|
|
|
|
|
$ 35,532
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment |
|
|
|
|
|
20,302
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets |
|
|
|
|
|
$ 18,114
|
|
|
|
|
Cash paid to the shareholders |
|
437,661
|
|
|
|
|
|
|
|
|
Business Combination, Consideration Transferred, Liabilities Incurred |
|
1,660
|
|
|
|
|
|
|
|
|
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life |
|
|
|
|
|
11 years
|
|
|
|
|
Goodwill |
|
|
|
|
|
$ 221,960
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt |
|
|
|
|
|
45,171
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|
|
|
|
|
$ 412,097
|
|
|
|
|
Horizon Discovery Group plc [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Entity Number of Employees | employees |
|
|
|
|
|
400
|
|
|
|
|
Shandong Meizheng [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Compensation Expense, Excluding Cost of Good and Service Sold |
2,100
|
|
$ 200
|
13,800
|
$ 6,900
|
|
|
|
|
|
Diagnostics [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Goodwill |
1,979,703
|
|
|
1,979,703
|
|
$ 1,691,227
|
|
|
|
|
Discovery & Analytical Solutions [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Goodwill |
5,440,568
|
|
|
5,440,568
|
|
1,755,887
|
|
|
|
|
Core Technology [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
285,609
|
|
|
285,609
|
|
|
|
|
|
|
Core Technology [Member] | BioLegend [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
782,400
|
|
|
782,400
|
|
|
|
|
|
|
Core Technology [Member] | Fiscal Year 2020 Acquisitions [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
|
|
|
|
|
65,730
|
|
|
|
|
Customer Relationships [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
141,170
|
|
|
141,170
|
|
|
|
|
|
|
Customer Relationships [Member] | BioLegend [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
1,714,800
|
|
|
1,714,800
|
|
|
|
|
|
|
Customer Relationships [Member] | Fiscal Year 2020 Acquisitions [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
|
|
|
|
|
108,523
|
|
|
|
|
Trade Names [Member] | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
39,620
|
|
|
39,620
|
|
|
|
|
|
|
Trade Names [Member] | BioLegend [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
$ 38,000
|
|
|
38,000
|
|
|
|
|
|
|
Trade Names [Member] | Fiscal Year 2020 Acquisitions [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
|
|
|
|
|
5,580
|
|
|
|
|
In-process Research and Development [Member] | Fiscal Year 2020 Acquisitions [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |
|
|
|
|
|
$ 10,700
|
|
|
|
|
United States of America, Dollars | Oxford Immunotec [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments |
|
|
|
590,900
|
|
|
|
|
|
|
United States of America, Dollars | Fiscal Year 2021 Acquisitions (Excluding BioLegend) [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments |
|
|
|
1,200,000
|
|
|
|
|
|
|
United States of America, Dollars | Nexcelom Bioscience [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments |
|
|
|
267,100
|
|
|
|
|
|
|
United States of America, Dollars | BioLegend [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments |
|
|
|
5,700,000
|
|
|
|
|
|
|
United States of America, Dollars | Fiscal Year 2021 Other Acquisitions [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments |
|
|
|
296,000
|
|
|
|
|
|
|
United States of America, Dollars | Fiscal Year 2020 Acquisitions [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments |
|
438,900
|
|
|
|
|
|
|
|
|
United States of America, Dollars | Horizon Discovery Group plc [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments |
|
399,800
|
|
|
|
|
|
|
|
|
United States of America, Dollars | Fiscal Year 2020 Other Acquisitions |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments |
|
39,100
|
|
|
|
|
|
|
|
|
United Kingdom, Pounds | Horizon Discovery Group plc [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments |
|
$ 296,000
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents [Member] | BioLegend [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Cash paid to the shareholders |
|
|
|
252,600
|
|
|
|
|
|
|
Senior Unsecured Notes [Member] | BioLegend [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Cash paid to the shareholders |
|
|
|
2,300,000
|
|
|
|
|
|
|
Line of Credit, Maturing August 24, 2026 [Member] | BioLegend [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Cash paid to the shareholders |
|
|
|
310,000
|
|
|
|
|
|
|
Term Loan Credit Facility Maturing 2024 [Member] | BioLegend [Member] |
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
Cash paid to the shareholders |
|
|
|
$ 500,000
|
|
|
|
|
|
|